Stocksigma LogoStocksigma Logo

Ind-Swift Laboratories Completes Preferential Issue Proceeds Utilization in Q2FY27

Ind-Swift Laboratories fully utilized its preferential issue proceeds as of 30th Sep'26, concluding with a final deployment of Rs

Ind-Swift Laboratories Completes Preferential Issue Proceeds Utilization in Q2FY27

Ind-Swift Laboratories Ltd 路 Others (Uncategorized) 路 03 Nov 2026, 8:17 pm

Ind-Swift Laboratories Completes Preferential Issue Proceeds Utilization in Q2FY27 Ind-Swift Laboratories fully utilized its preferential issue proceeds as of 30th Sep'26, concluding with a final deployment of Rs. 3.77 crore in Q2FY27 toward business expansion. Total funds raised and utilized reached Rs. 255.61 crore out of the targeted Rs. 314.60 crore, as 65 lakh warrants lapsed due to non-conversion by Saral Incorporated VCC Sub Fund 1, causing a Rs. 58.99 crore shortfall. The company confirmed that this shortfall will be funded via internal accruals, with unutilized issue proceeds standing at zero.

Original exchange filing (PDF)

More announcements from Ind-Swift Laboratories Ltd

All Ind-Swift Laboratories Ltd announcements